Abstract
Recent studies of adults have found an association between hyperintensity of the dentate nucleus (DN) and globus pallidus (GP) on T1 -weighted images (T1 WI) and a history of linear gadolinium-based contrast agent (GBCA) administration. Several reports have also focused on this phenomenon in pediatric patients; however, data in the current literature remains limited. To evaluate the associations between DN and GP T1 -signal increase and previous administration of linear GBCAs in pediatric patients. Single-center, retrospective, cross-sectional study. We included pediatric patients with histories of ≥5 linear GBCA (gadodiamide and gadopentetate dimeglumine) administrations (the "≥5 Linear GBCA administrations" group), 1-4 administrations (the "1-4 Linear GBCA administrations" group), and no history of GBCA administration (the "No GBCA administration" group). Each group included 42 patients. Therefore, 126 patients (male:female, 72:54; median age, 16 [range, 4-18] years) were included in this study. 1.5T/ Spin-echo unenhanced T1 -weighted imaging. Unenhanced T1 -weighted images were quantitatively analyzed by two radiologists. The DN-to-pons and GP-to-thalamus signal intensity ratios (DN-to-pons and GP-to-thalamus ratios, respectively) were compared. Wilcoxon test with the Bonferroni correction and intraclass correlation coefficients. The DN-to-pons ratio increased as the number of GBCA administrations increased (P < 0.0063). The GP-to-thalamus ratio of the "≥5 Linear GBCA administrations" group was significantly higher than those of the other two groups (P < 0.0001). The GP-to-thalamus ratio of the "1-4 Linear GBCA administrations" group did not differ significantly from that of the "No GBCA administration" group (P = 1.000). The DN-to-pons and GP-to-thalamus ratios' interobserver intraclass correlation coefficients were excellent (0.8236) and good (0.6738), respectively. High signal intensities in the DN and GP on T1 WI were associated with previous linear GBCA administration in pediatric patients. 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:1046-1052.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have